Zymeworks Inc. is a privately held, clinical-stage, biotherapeutics company based in Vancouver, British Columbia. Zymeworks is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.

Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks is developing multiple therapeutic candidates based on novel platform technologies to advance the field of biologics drug discovery and optimization.

Zymeworks was incorporated in 2003 to address a need in the pharmaceutical and chemical markets that was not served by the existing protein simulation and engineering approaches. At the time, the market and scientific community were segregated into two very distinct approaches. The first approach included widely distributed, open-source academic projects that were advancing the science at a very rapid pace, however sometimes at the expense of commercially relevant concerns including usability, modularity, documentation, and an overall focus on the needs of pharmaceutical and chemical companies. The second approach included legacy in silico platforms that had been adapted for certain specific commercial purposes, but failed to capture recent advances in protein biochemistry or computing architecture.

Zymeworks addressed the shortcomings of both of these approaches. The ZymeCAD™ engine was designed and built from the ground up to be the most comprehensive platform for in silico protein modeling and engineering, incorporating advanced hot spot identification and mutagenesis tools in a modular and scalable platform. Today, Zymeworks has successfully leveraged the ZymeCAD™ engine into leading biologics platforms that enables the development of several therapeutic candidates.

Zymeworks is leveraging its novel antibody and alternative protein platforms to develop a diverse pipeline of novel antibody therapeutics that includes first-in-class and best-in-class candidates to help mitigate the risk and uncertainty associated with new target discovery and validation. Zymeworks intends to clinically develop a number of therapeutic candidates and plans to partner a subset once meaningful clinical inflection points are reached.

Zymeworks is also forming highly-strategic collaborative drug development partnerships with major pharmaceutical partners to provide them access to, while expanding and diversifying the therapeutic applications for, Zymeworks’ platforms. Throughout the lifespan of these programs Zymeworks benefits from upfront payments, near-term research and development milestones and long-term royalty streams.